1. Resources
  2. Citations Library

Citation Details

You are viewing citation details. You can save or export citation(s) below, access an article, or start a new search.

1–1 of 1 record found matching your query:
Back to Search
Select All  |  Deselect All

Headers act as filters

      1. Author :
        Iankov, ID; Kurokawa, CB; D'Assoro, AB; Ingle, JN; Domingo-Musibay, E; Allen, C; Crosby, CM; Nair, AA; Liu, MC; Aderca, I
      2. Title :
        Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy
      3. Type :
        Journal Article
      4. Year :
        2015
      5. Publication :
        Cancer gene therapy
      6. Products :
      7. Volume :
        22
      8. Issue :
        9
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Ivis
      12. Abstract :
        Oncolytic measles virus (MV) strains have demonstrated broad spectrum preclinical anti-tumor efficacy, including breast cancer. Aurora A kinase controls mitotic spindle formation and has a critical role in malignant transformation. We hypothesized that the Aurora A kinase inhibitor MLN8237 (alisertib) can increase MV oncolytic effect and efficacy by causing mitotic arrest. Alisertib enhanced MV oncolysis in vitro and significantly improved outcome in vivo against breast cancer xenografts. In a disseminated MDA-231-lu-P4 lung metastatic model, the MV/alisertib combination treatment markedly increased median survival to 82.5 days with 20% of the animals being long-term survivors versus 48 days median survival for the control animals. Similarly, in a pleural effusion model of advanced breast cancer, the MV/alisertib combination significantly improved outcome with a 74.5 day median survival versus the single agent groups (57 and 40 days, respectively). Increased viral gene expression and IL-24 upregulation were demonstrated, representing possible mechanisms for the observed increase in anti-tumor effect. Inhibiting Aurora A kinase with alisertib represents a novel approach to enhance MV-mediated oncolysis and antitumor effect. Both oncolytic MV strains and alisertib are currently tested in clinical trials, this study therefore provides the basis for translational applications of this combinatorial strategy in the treatment of patients with advanced breast cancer.
      13. URL :
        N/A
      14. Call Number :
        PKI @ user @ 9974
      15. Serial :
        20756
Back to Search
Select All  |  Deselect All